Health System Factors in Head and Neck Cancer Diagnosis: A HEADSpAcE Consortium Qualitative Study in Glasgow and Montevideo - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Factors Within Healthcare Systems Affecting Diagnosis of Head and Neck Cancer: Insights from a Qualitative Study by the HEADSpAcE Consortium in Glasgow and Montevideo

  • By

  • Grant Creaney

  • Iván Lyra González

  • Mauricio Cuello

  • Mariél de Aquino Goulart

  • Alex D. McMahon

  • Claire Paterson

  • James McCaul

  • Maja Popovic

  • Lorenzo Richiardi

  • Silvia Lopez de Blanc

  • Maria Paula Curado

  • Marta Vilensky

  • Shaymaa Alwaheidi

  • Paul Brennan

  • Shama Virani

  • Al Ross

  • David I Conway

  • May 10, 2026

Share

  • 1

    Head and neck cancer (HNC) ranks seventh globally for incidence, with approximately 600,000 new cases diagnosed annually.

  • 2

    More than half of HNC cases present at an advanced stage, highlighting the importance of early diagnosis for better outcomes.

  • 3

    Diagnosis of HNC requires a well-defined pathway and access to multidisciplinary teams and diagnostic resources.

  • 4

    Health system factors, including the availability of diagnostic facilities, influence the stage at which HNC is diagnosed.

  • 5

    The study involved 29 interviews across Glasgow and Montevideo to explore health system variables affecting HNC diagnosis.

Original Source(s)

Health System Factors in Head and Neck Cancer Diagnosis: A HEADSpAcE Consortium Qualitative Study in Glasgow and Montevideo

  • by Grant Creaney, Iván Lyra González, Mauricio Cuello, Mariél de Aquino Goulart, Alex D. McMahon, Claire Paterson, James McCaul, Maja Popovic, Lorenzo Richiardi, Silvia Lopez de Blanc, Maria Paula Curado, Marta Vilensky, Shaymaa Alwaheidi, Paul Brennan, Shama Virani, Al Ross, David I Conway

  • May 10, 2026

Related Content

Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min
Intraoperative Evaluation of Sarcoma Surgical Margins With Indocyanine Green Fluorescence Imaging: Results From an Observational Study